Trial Profile
Effect of brentuximab vedotin in patients with refractory hodgkin and anaplastic large cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology